| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1028122579 |
| P356 | DOI | 10.1007/S40122-016-0060-3 |
| P932 | PMC publication ID | 5130910 |
| P698 | PubMed publication ID | 27822619 |
| P50 | author | G H Hans | Q73482497 |
| Victor Mayoral | Q80820711 | ||
| Massimo Allegri | Q37839516 | ||
| P2093 | author name string | Ralf Baron | |
| Michael Serpell | |||
| Gerard Mick | |||
| Gerardo Correa-Illanes | |||
| P2860 | cites work | The Epidemiology of Chronic Pain of Predominantly Neuropathic Origin. Results From a General Population Survey | Q21710682 |
| Recommendations for the pharmacological management of neuropathic pain: an overview and literature update | Q24616897 | ||
| Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up | Q24649099 | ||
| TRPV1: on the road to pain relief | Q24650367 | ||
| The topical 5% lidocaine medicated plaster in localized neuropathic pain: a reappraisal of the clinical evidence | Q26765263 | ||
| A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain | Q26991960 | ||
| GRADE: an emerging consensus on rating quality of evidence and strength of recommendations | Q27860753 | ||
| Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis | Q28085455 | ||
| Mechanisms of Disease: neuropathic pain—a clinical perspective | Q29542874 | ||
| Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment | Q30458126 | ||
| Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology | Q31116868 | ||
| Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin | Q33213049 | ||
| The impact of herpes zoster and post-herpetic neuralgia on quality-of-life | Q33611436 | ||
| Reduction of painful area as new possible therapeutic target in post-herpetic neuropathic pain treated with 5% lidocaine medicated plaster: a case series | Q33824504 | ||
| Simultaneous comparison of multiple treatments: combining direct and indirect evidence. | Q34081552 | ||
| EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision | Q34110857 | ||
| Postherpetic neuralgia: irritable nociceptors and deafferentation | Q34483000 | ||
| Neuropathic pain: an updated grading system for research and clinical practice | Q34523633 | ||
| EFNS guidelines on pharmacological treatment of neuropathic pain. | Q34573607 | ||
| Outcome predictors for treatment success with 5% lidocaine medicated plaster in low back pain with neuropathic components and neuropathic pain after surgical and nonsurgical trauma | Q34623739 | ||
| Prevalence of chronic pain with neuropathic characteristics in the general population. | Q34691911 | ||
| Pharmacologic management of neuropathic pain: evidence-based recommendations | Q34699259 | ||
| Patient perceptions associated with the 5% lidocaine medicated plaster in daily practice | Q39249182 | ||
| Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers | Q39257723 | ||
| Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study | Q39286848 | ||
| Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. | Q39303996 | ||
| Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled tri | Q39306047 | ||
| Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial | Q39381532 | ||
| Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain | Q39384834 | ||
| More than 7 years of consistent neuropathic pain relief in geriatric patients | Q39397259 | ||
| Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study | Q39438845 | ||
| The effects of lidocaine on nitric oxide production from an activated murine macrophage cell line | Q40835201 | ||
| Early experience with lidocaine patch for postoperative pain control after laparoscopic ventral hernia repair | Q42601411 | ||
| Inhibitory effect of lidocaine on T cells from patients with allergic asthma | Q43920208 | ||
| Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster | Q43971736 | ||
| Micromolar lidocaine selectively blocks propagating ectopic impulses at a distance from their site of origin | Q44140996 | ||
| Assessment of pain and impact of care among patients with painful diabetic peripheral neuropathy | Q44487547 | ||
| Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy | Q44946961 | ||
| Pain and dysesthesia in patients with spinal cord injury: A postal survey. | Q45081571 | ||
| Lidocaine patch (5%) in treatment of persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled, crossover trial. | Q45143398 | ||
| Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy. | Q46008444 | ||
| Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics | Q46083277 | ||
| A pharmacological treatment algorithm for localized neuropathic pain | Q47619254 | ||
| Lidocaine 5% Patch for Treatment of Acute Pain After Robotic Cardiac Surgery and Prevention of Persistent Incisional Pain: A Randomized, Placebo-Controlled, Double-Blind Trial | Q47675734 | ||
| Lidocaine patch for acute pain management: a meta-analysis of prospective controlled trials | Q47803271 | ||
| Unmet need in the treatment of postherpetic neuralgia | Q48021520 | ||
| The specific disease burden of neuropathic pain: results of a French nationwide survey. | Q48277522 | ||
| Management of neuropathic pain after surgical and non-surgical trauma with lidocaine 5% patches: study of 40 consecutive cases. | Q48405053 | ||
| Post-surgical neuropathic pain | Q48486589 | ||
| painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain | Q48488749 | ||
| Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey | Q48549221 | ||
| Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale | Q48823789 | ||
| What is localized neuropathic pain? A first proposal to characterize and define a widely used term. | Q53138460 | ||
| Incidence of central post-stroke pain | Q56453968 | ||
| The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study | Q70651014 | ||
| Central pain in multiple sclerosis--prevalence and clinical characteristics | Q81155015 | ||
| The burning case of neuropathic pain wording | Q81545602 | ||
| Allodynic skin in post-herpetic neuralgia: histological correlates | Q83902062 | ||
| The clinical implications of cytochrome p450 interactions with opioids and strategies for pain management | Q85632841 | ||
| Neuropathic pain: redefinition and a grading system for clinical and research purposes | Q34713765 | ||
| Treatment of localized neuropathic pain of different etiologies with the 5% lidocaine medicated plaster - a case series. | Q34783788 | ||
| Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study | Q34994547 | ||
| Treatment of neuropathic pain: an overview of recent guidelines | Q35006269 | ||
| Differential modulation of Nav1.7 and Nav1.8 peripheral nerve sodium channels by the local anesthetic lidocaine | Q35047167 | ||
| Treatment of neuropathic pain with 5% lidocaine-medicated plaster: Five years of clinical experience | Q35453240 | ||
| 5% Lidocaine Medicated Plaster for the Treatment of Postherpetic Neuralgia: A Review of the Clinical Safety and Tolerability | Q35752545 | ||
| Treatment of postherpetic neuralgia: a review of therapeutic options | Q35911962 | ||
| Treatment of localized post-traumatic neuropathic pain in scars with 5% lidocaine medicated plaster | Q36160742 | ||
| Treatment of localized neuropathic pain after disk herniation with 5% lidocaine medicated plaster | Q36196787 | ||
| Algorithm for neuropathic pain treatment: an evidence based proposal. | Q36280904 | ||
| Use of 5% lidocaine medicated plaster to treat localized neuropathic pain secondary to traumatic injury of peripheral nerves | Q36395685 | ||
| Chronic post-surgical pain: 10 years on. | Q37146913 | ||
| Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient | Q37330295 | ||
| Postherpetic neuralgia in the elderly | Q37427315 | ||
| Lidocaine 5% medicated plaster: a review of its use in postherpetic neuralgia | Q37605781 | ||
| Assessment of neuropathic pain in primary care | Q37607764 | ||
| Pharmacological treatment of chronic pain - the need for CHANGE. | Q37718813 | ||
| 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. | Q37748623 | ||
| Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment | Q37774746 | ||
| 5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review | Q37805539 | ||
| Topical preparations for pain relief: efficacy and patient adherence | Q37851017 | ||
| New developments in the treatment algorithm for peripheral neuropathic pain | Q37900694 | ||
| Epidemiology of neuropathic pain and its impact on quality of life | Q37991227 | ||
| Topical pain management with the 5% lidocaine medicated plaster--a review | Q38007008 | ||
| Evidence-based guidance for the management of postherpetic neuralgia in primary care | Q38128177 | ||
| Reappraising neuropathic pain in humans--how symptoms help disclose mechanisms | Q38135692 | ||
| Topical therapies in the management of chronic pain | Q38189068 | ||
| Cognitive function in older patients with postherpetic neuralgia. | Q38451040 | ||
| Pharmacokinetics and safety of continuously applied lidocaine patches 5%. | Q38486616 | ||
| Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting | Q38488102 | ||
| Safety and efficacy outcomes of long-term treatment up to 4 years with 5% lidocaine medicated plaster in patients with post-herpetic neuralgia. | Q39245360 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lidocaine | Q216935 |
| neuropathic pain | Q2798704 | ||
| supporting evidence | Q110632057 | ||
| P304 | page(s) | 149-169 | |
| P577 | publication date | 2016-11-07 | |
| P1433 | published in | Pain and therapy | Q26842276 |
| P1476 | title | The 5% Lidocaine-Medicated Plaster: Its Inclusion in International Treatment Guidelines for Treating Localized Neuropathic Pain, and Clinical Evidence Supporting its Use | |
| P478 | volume | 5 |
| Q55364011 | Gaps in Understanding Mechanism and Lack of Treatments: Potential Use of a Nonhuman Primate Model of Oxaliplatin-Induced Neuropathic Pain. |
| Q90600752 | Lidocaine 5%-medicated plaster (Versatis) for localised neuropathic pain: results of a multicentre evaluation of use in children and adolescents |
| Q47094942 | Pharmacotherapy for Neuropathic Pain: A Review |
| Q47242634 | Post-herpetic neuralgia - a review of current management and future directions |
Search more.